Role of Cryobiopsy in Diagnosis of Pleural Effusion

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT03828903
Collaborator
(none)
60
2
1
19
30
1.6

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the feasibility, size and quality of the specimens obtained by cryoprobe in comparison to those specimens obtained by flexible forceps during medical thoracoscopy in diagnosis of pleural effusion.

Condition or Disease Intervention/Treatment Phase
  • Device: Cryoprobe
N/A

Detailed Description

  • Medical thoracoscopy with single-port-of-entry technique will be performed in the bronchoscopy unit under local anesthesia and conscious sedation using midazolam (2 mg) or pethidin.

  • vertical incision will be made with the scalpel (usually near the midaxillary line), through the skin and subcutaneous tissue, appropriate to the size of the trocar to be used, usually of approximately 10 mm, parallel with and in the middle of the selected intercostal space.

  • Then the trocar will be inserted until the sudden release of resistance (after passing the costal pleura) is felt.

  • Under direct vision with the thoracoscope, introduction of pneumothorax will be performed, and all pleural fluid will be removed, and the pleural cavity will be inspected.

  • Suspicious areas will be biopsied through the working channel of the thoracoscope.

  • two to six biopsies of a suspicious pleural lesion will establish the diagnosis.

Technique of pleural biopsy using cryotechnique:
  • The probe (ERBE Elektromedizin GmbH( Gesellschaft mit beschränkter Haftung) , Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.

  • The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch.

  • carbon dioxide will be used as the cryogen gas for cryobiopsy

  • The frozen tissue is going to be extracted by gently pulling of the probe.

  • Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Diagnostic Value of Cryobiopsy During Medical Thoracoscopy in Diagnosis of Pleural Effusion
Actual Study Start Date :
Mar 10, 2020
Actual Primary Completion Date :
Sep 10, 2021
Actual Study Completion Date :
Oct 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: pleural effusion patients

medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained

Device: Cryoprobe
The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization. The tip of the cryoprobe will be attached to suspicious part of parietal pleura . The frozen tissue is going to be extracted by gently pulling of the probe. Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline. The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding.

Outcome Measures

Primary Outcome Measures

  1. comparison between pleural biopsy specimens obtained by flexible forceps with those obtained with cryoprobe during medical thoracoscopy in diagnosis of pleural effusion. [12 months]

    1_size of pleural biopsy obtained by cryoprobe in comparison to those obtained by flexible forceps (in millimeter).

Secondary Outcome Measures

  1. Complication assessment [12 months]

    To evaluate the safety and occurrence of complication such as bleeding Number of patients with a certain degree of bleeding from biopsy site, described as: 1 = slight, self-limited, 2 = moderate, requiring electrocautery intervention, 3 = severe, requiring interruption of the procedure, chest tube drainage and intravenous fluid resuscitation .

  2. assessment pleural fluid [12 months]

    comparison between the estimate of pleural effusion using chest ultrasound and actual amount after thoracoscpic drainage, measured in mililiters.

  3. assessment of post procedure pain [12 months]

    comparison between meperidine and (midazolam &NSAIDs) in controlling pain post thoracoscopy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. Unilateral moderate or massive exudative pleural effusion patients. 2. Undiagnosed pleural effusion after simple pleural fluid aspiration, cytology or blind (closed) pleural biopsy using Abram's needle.
  1. Age>18 years old
Exclusion Criteria:
  1. Transudative pleural effusion.

  2. Exudative pleural effusion less than one third of hemithorax.

  3. Presence of hemorrhagic diathesis (prothrombin concentration <50% and platelet count <80,000/mm 3).

  4. Poor performance state (ECOG performance status >4) as recommended in BTS (British thoracic society) guidelines 2010.

  5. Sever uncontrollable cough, hypercapnia and sever respiratory distress.

  6. Fibrothorax, excessive pleural adhesion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assuit University hospital Assiut Egypt 71511
2 Alaa Salah Abdel gany Assiut Egypt

Sponsors and Collaborators

  • Assiut University

Investigators

  • Principal Investigator: Reham M El morshedy, Lecturer, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Alaa Salah Abd El Ghany, Assistant lecturer, Chest Department and tuberculosis, Assiut University
ClinicalTrials.gov Identifier:
NCT03828903
Other Study ID Numbers:
  • Cryobiopsy pleural effusion
First Posted:
Feb 4, 2019
Last Update Posted:
Dec 9, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alaa Salah Abd El Ghany, Assistant lecturer, Chest Department and tuberculosis, Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 9, 2021